Study of SD-101 in Combination With Localized Low-dose Radiation in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Withdrawn	`NCT05929716` - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma	Phase 2
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Recruiting	`NCT05016947` - Venetoclax Plus Inotuzumab for B-ALL	Phase 1
Completed	`NCT02900716` - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas	Phase 1
Completed	`NCT03068416` - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy	Phase 2
Not yet recruiting	`NCT05014100` - Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma	Phase 2
Recruiting	`NCT05934838` - A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas	Phase 1
Terminated	`NCT04023071` - FT516 in Subjects With Advanced Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT04148430` - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy	Phase 2
Completed	`NCT02933320` - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	Phase 1/Phase 2
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Completed	`NCT02741388` - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP	Phase 1
Completed	`NCT02300402` - Detection and Characterization of Residual Masses in Lymphomas
Terminated	`NCT00906841` - Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma	Phase 2
Completed	`NCT00338494` - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma	Phase 1
Recruiting	`NCT05487651` - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies	Phase 1
Withdrawn	`NCT05570188` - Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT03281551` - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma	Phase 1
Completed	`NCT03734601` - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation	Phase 2

NCT number	NCT02266147
Study type	Interventional
Source	Dynavax Technologies Corporation
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	October 2014
Completion date	April 2017

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms